Loading clinical trials...
Loading clinical trials...
Phase II Clinical Trial With an Adaptive Design According to Response to Cemiplimab Monotherapy Using ctDNA and Subsequent Treatment With Chemotherapy (CT) and Cemiplimab or Cemiplimab Monotherapy in First Line Advanced NSCLC Patients
Conditions
Interventions
Cemiplimab
Carboplatin
+1 more
Locations
20
Spain
Hospital General de Alicante
Alicante, Alicante, Spain
Hospital General de Elche
Elche, Alicante, Spain
ICO Badalona, Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital Universitari Vall d' Hebron
Barcelona, Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, Spain
ICO Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Start Date
July 29, 2025
Primary Completion Date
December 30, 2031
Completion Date
December 30, 2031
Last Updated
November 19, 2025
NCT05722340
NCT05948904
NCT04707781
NCT07300696
NCT07227376
NCT06585020
Lead Sponsor
Fundación GECP
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions